Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: The Multistrategy randomized trial

JAMA

Volumn 299, Issue 15, 2008, Pages 1788-1799

  Valgimigli, Marco ^a,b   Campo, Gianluca ^b   Percoco, Gianfranco ^a   Bolognese, Leonardo ^c   Vassanelli, Corrado ^d   Colangelo, Salvatore ^e   De Cesare, Nicoletta ^f   Rodriguez, Alfredo E ^g   Ferrario, Maurizio ^h   Moreno, Raul ⁱ   Piva, Tommaso ^j   Sheiban, Imad ^k   Pasquetto, Giampaolo ^l   Prati, Francesco ^m   Nazzaro, Marco S ⁿ   Parrinello, Giovanni ^o   Ferrari, Roberto ^a,b  

^a UNIVERSITY OF FERRARA   (Italy)

^b IRCCS   (Italy)

^c IRCCS POLICLINICO SAN DONATO   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e MOLINETTE HOSPITAL   (Italy)

^f UO Neurologia Policlinico San Marco   (Italy)

^g Sanatorio Otamendi y Miroli   (Argentina)

^h FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

ⁱ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^j Azienda Ospedaliera Umberto I   (Italy)

^k UNIVERSITY OF TURIN   (Italy)

^l Civic Hospital   (Italy)

^m CATHOLIC UNIVERSITY   (Italy)

ⁿ SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^o UNIVERSITY OF BRESCIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAPAMYCIN; TICLOPIDINE; TIROFIBAN; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; TYROSINE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOPLASTY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ELUTING STENT; DRUG FATALITY; DRUG MEGADOSE; ELECTROCARDIOGRAPHY; FACTORIAL DESIGN; FEMALE; HEART DISEASE; HEART LEFT BUNDLE BRANCH BLOCK; HEART REINFARCTION; HUMAN; IMPLANTATION; ISCHEMIA; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MATERIAL COATING; MULTICENTER STUDY; PATIENT REFERRAL; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; SIDE EFFECT; ST SEGMENT ELEVATION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; COMPARATIVE STUDY; DRUG ANTAGONISM; HEART INFARCTION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; DRUG-ELUTING STENTS; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STENTS; TYROSINE;

EID: 42249090036     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.299.15.joc80026     Document Type: Article

References (43)

1. Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol. 2003;42(11):1886-1889.
2. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005;293(14):1759-1765.
3. Montalescot G, Antoniucci D, Kastrati A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J. 2007;28(4):443-449.
4. Nordmann AJ, Bucher H, Hengstler P, Harr T, Young J. Primary stenting versus primary balloon angioplasty for treating acute myocardial infarction. Cochrane Database Syst Rev. 2005;(2):CD005313.
5. Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administered with the highdose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol. 2004;44(1):14-19.
6. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and baremetal stent for acute myocardial infarction: a randomized trial. JAMA. 2005;293(17):2109-2117.
7. Farb A, Boam AB. Stent thrombosis redux: the FDA perspective. N Engl J Med. 2007;356(10):984-987.
8. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006;355(11):1105-1113.
9. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006;355(11):1093- 1104.
10. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drugeluting stent placement: results from the PREMIER registry. Circulation. 2006;113(24):2803-2809.
11. Valgimigli M, Bolognese L, Anselmi M, et al. Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEGY trial. Am Heart J. 2007;154(1):39-45.
12. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings. N Engl J Med. 1985;312(14):932-936.
13. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344-2351.
14. Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol. 2003;42(11):1879-1885.
15. Sauerbrei W. The use of resampling methods to simplify regression models in medical statistics. Appl Stat. 1999;48:313-329.
16. Austin PC, Tu JV. Bootstrap methods for developing predictive models. Am Stat. 2004;58(2):131-137.
17. Frossard M, Fuchs I, Leitner JM, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation. 2004;110(11):1392-1397.
18. Campo G, Valgimigli M, Gemmati D, et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J Am Coll Cardiol. 2006;48(11):2178-2185.
19. Huczek Z, Filipiak KJ, Kochman J, et al. Baseline platelet reactivity in acute myocardial infarction treated with primary angioplasty: influence on myocardial reperfusion, left ventricular performance, and clinical events. Am Heart J. 2007;154(1):62-70.
20. Antoniucci D, Migliorini A, Parodi G, et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone. Circulation. 2004;109(14):1704-1706.
21. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet. 1999;353(9148):227-231.
22. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344(25):1888-1894.
23. Schneider DJ, Herrmann HC, Lakkis N, et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol. 2003;91(3):334-336.
24. Danzi GB, Capuano C, Sesana M, Mauri L, Sozzi FB. Variability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention. Am J Cardiol. 2006;97(4):489-493.
25. Ernst NM, Suryapranata H, Miedema K, et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004;44(6):1187-1193.
26. Bolognese L, Falsini G, Liistro F, et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J Am Coll Cardiol. 2006;47(3):522-528.
27. Danzi GB, Sesana M, Capuano C, Mauri L, Berra Centurini P, Baglini R. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function. Am J Cardiol. 2004;94(1):35-39.
28. TENACITY trial officially halted; Guilford seeks partner or buyer for tirofiban. http://www.theheart.org/viewArticle.do?primaryKey=516083&from=/ searchLayout.do. Accessed January 9, 2008.
29. Merlini PA, Rossi M, Menozzi A, et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation. 2004;109(18):2203-2206.
30. Aster RH, Curtis BR, Bougie DW, et al. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost. 2006;4(3):678-679.
31. Lele M, Sajid M, Wajih N, Stouffer GA. Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v) beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin. Circulation. 2001;104(5):582-587.
32. Reininger AJ, Agneskirchner J, Bode PA, Spannagl M, Wurzinger LJ. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/ IIIa as well as endothelial vitronectin receptor: results from patients with acute myocardial infarction and healthy controls. Thromb Haemost. 2000;83(2):217-223.
33. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015.
34. Valgimigli M, Percoco G, Bolognese L. Drugeluting stents in primary PCI. N Engl J Med. 2006;355(23):2484.
35. Pinto DS, Stone GW, Ellis SG, et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol. 2006;48(1):32-36.
36. Applegate RJ, Sacrinty MT, Kutcher MA, et al. "Off-label" stent therapy 2-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2008;51(6):607-614.
37. Roe MT, Ohman EM, Maas AC, et al. Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. J Am Coll Cardiol. 2001;37(1):9-18.
38. Dong J, Ndrepepa G, Schmitt C, et al. Early resolution of ST-segment elevation correlates with myocardial salvage assessed by Tc-99m sestamibi scintigraphy in patients with acute myocardial infarction after mechanical or thrombolytic reperfusion therapy. Circulation. 2002;105(25):2946-2949.
39. O'Neill WW, Martin JL, Dixon SR, et al. Acute Myocardial Infarction with Hyperoxemic Therapy (AMIHOT): a prospective, randomized trial of intracoronary hyperoxemic reperfusion after percutaneous coronary intervention. J Am Coll Cardiol. 2007;50(5):397-405.
40. Stoel MG, Marques KM, de Cock CC, Bronzwaer JG, von Birgelen C, Zijlstra F. High dose adenosine for suboptimal myocardial reperfusion after primary PCI: a randomized placebo-controlled pilot study. Catheter Cardiovasc Interv. 2008;71(3):283-289.
41. Gershlick AH, Stephens-Lloyd A, Hughes S, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med. 2005;353(26):2758-2768.
42. van 't Hof AW, Liem A, de Boer MJ, Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction: Zwolle Myocardial infarction Study Group. Lancet. 1997;350(9078):615-619.
43. Schroder R. Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation. 2004;110(21):e506-e510.